<DOC>
	<DOCNO>NCT00176644</DOCNO>
	<brief_summary>Multiple trial show efficacy estrogen therapy metastatic prostate cancer , recently trial support use transdermal estrogen ( patch ) patient population decrease risk cardiovascular disease compare oral estrogen . We plan study use transdermal estrogen dose 0.4mg qd . We evaluate toxicity measure quality life . We assess PSA response measurable disease response . This trial available Cancer Institute New Jersey Oncology Group . We enroll total 33 patient . We plan enroll 10 CINJ.Patients wear patch ( 4 ) continuously . We obtain blood work clinic evaluation every three week . We assess quality life questionnaire give patient every three week .</brief_summary>
	<brief_title>Phase II Trial Transdermal Estradiol Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Inclusion Criteria Patients metastatic prostate adenocarcinoma , fail initial hormone therapy progression least one chemotherapy regimen include docetaxel . Patients antiandrogens must progression withdrawal antiandrogen 4 week ( flutamide ) 6 week ( bicalutamide ) . PSA ≥ 10 ng/ml . Patients receive LHRH agonist therapy &gt; 1 month must maintain agonist therapy onstudy . Patients receive agonist therapy receive &lt; 1 month therapy , may begin continue agonist therapy onstudy . Age &gt; 18 year estimate life expectancy least 4 month . ECOG performance status ≤ 2 ( see Appendix B ) . Full recovery effect prior surgery radiation therapy within 4 week study entry . Serum creatinine ≤ 1.5 x ULN Total bilirubin &lt; ULN Transaminases ( SGOT and/or SGPT ) ≤ 2 X institutional upper limit . Capacity give informed , write consent . Exclusion Criteria Any coexist medical condition preclude full compliance study . Any history deep venous thrombosis ( DVT ) pulmonary embolus . Patients DVT anticoagulant ≥ 6 month eligible . Known CNS metastasis . The discontinuation flutamide bicalutamide &lt; 4 6 week respectively . History severe cardiovascular disease ( AHA class III IV ; see Appendix C ) , uncontrolled CHF life threaten cardiac dysrhythmia past 6 month . Herbal supplement may use onstudy patient must discontinue use ≥ 1 week enter onstudy . Patients know hypersensitivity estrogen . Triglyceride &gt; 200 mg/dl . Prior estramustine .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>prostate cancer</keyword>
</DOC>